Skip to content

Study · Non-randomized trial · n = 18 · 1989

3 results

Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures.

Pun KK, Chan LW

Clinical therapeutics1 Mar 1989Cited by 85 (Europe PMC)

PMID2660996 (opens in a new tab)PepBankPUB-02660996
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with acute osteoporotic vertebral collapse, nasal salmon calcitonin significantly relieved pain compared with placebo.

    In plain wordsIn patients with acute osteoporotic vertebral collapse, nasal salmon calcitonin relieved pain more than placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreasePain
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    200 IU per day · intranasalAs given in this study (human).

    Source sentences

    Summary
    When compared with placebo, intranasal salmon calcitonin significantly relieved pain and occasioned a decrease in the consumption of analgesic drugs.
    2 context sentences
    Summary · context
    In this study, the analgesic effect of salmon calcitonin, administered intranasally (200 IU per day), was assessed in 18 patients with acute collapse of one to four vertebrae.
    Summary · context
    Pain was evaluated by a descriptive pain scale (ie, Keele's) as well as by the daily consumption of analgesic drugs.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with acute osteoporotic vertebral collapse, nasal salmon calcitonin reduced analgesic consumption compared with placebo.

    In plain wordsIn patients with acute osteoporotic vertebral collapse, nasal salmon calcitonin reduced pain medicine use compared with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseAnalgesic consumption
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    200 IU per day · intranasalAs given in this study (human).

    Source sentences

    Summary
    When compared with placebo, intranasal salmon calcitonin significantly relieved pain and occasioned a decrease in the consumption of analgesic drugs.
    2 context sentences
    Summary · context
    In this study, the analgesic effect of salmon calcitonin, administered intranasally (200 IU per day), was assessed in 18 patients with acute collapse of one to four vertebrae.
    Summary · context
    Pain was evaluated by a descriptive pain scale (ie, Keele's) as well as by the daily consumption of analgesic drugs.
  3. 03HumanNon-randomized trialSafety outcome

    In the nasal salmon calcitonin study of acute vertebral collapse, patients reported no major side effects.

    In plain wordsPatients in the nasal salmon calcitonin study reported no major side effects.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableMajor side effects
    Study

    n = 18

    Outcome group
    Adverse events · Whole body
    Studied dose
    200 IU per day · intranasalAs given in this study (human).

    Source sentences

    Summary
    No major side effects were reported by the patients under study.
    2 context sentences
    Summary · context
    In this study, the analgesic effect of salmon calcitonin, administered intranasally (200 IU per day), was assessed in 18 patients with acute collapse of one to four vertebrae.
    Summary · context
    Pain was evaluated by a descriptive pain scale (ie, Keele's) as well as by the daily consumption of analgesic drugs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.